Dihexa is an unapproved, animal-stage research compound with no human trials and no validated dosing framework. This page stays conceptual: any amounts people mention are anecdotal, not medically established, and vary widely. Any use should start low and be supervised by a qualified clinician.
Overview
Dihexa is a synthetic derivative of angiotensin IV, engineered for stability and studied preclinically for effects on synapse formation. It is frequently described as highly potent in animal models — but preclinical potency says nothing about a safe human amount, and no human dosing has been established.
What the community reports
Because there is no approved framework, this page deliberately avoids a fixed protocol. In general terms:
- Community accounts describe small amounts, taken orally or by injection, reflecting the compound's reported high potency.
- The specific figures people cite vary widely, are anecdotal, and are not well-established — there is no validated range to anchor them.
- "Highly potent in animals" is a reason for more caution, not a green light for self-experimentation.
How it is administered
Dihexa is marketed as a research powder — sometimes for oral use, sometimes reconstituted for injection.
- For reconstituted forms, any amount depends on concentration — how much diluent is added — which makes small-amount errors easy.
- As an unregulated compound, actual content and purity are not verified, so a label may not match the vial.
Why oversight matters
Dihexa's mechanism intersects with growth-factor signalling, and its human pharmacokinetics and safety are simply unknown. There is no monitoring standard, no antidote framework, and no trial data to fall back on. This is why the topic stays conceptual — meaningful decisions belong within controlled research under expert supervision.